Compositions and methods of use thereof
AssigneeSynedgen, Inc.
InventorsShenda Baker, William P. Wiesmann, Stacy Marie Townsend
Life of this patent
Estimating the term…
Abstract
Described herein are methods for treating or preventing a disease or disorder of the pulmonary system (e.g., cystic fibrosis), respiratory or digestive system in a subject, the methods comprising administering compounds or compositions comprising water soluble polyglucosamine and derivatized polyglucosamine.
Claims128
A method for treating a subject suffering from a mucosal disease or disorder, comprising administering an effective amount of a poly (acetyl, arginyl) glucosamine (PAAG) comprising the following formula (I):
- wherein:
- n is an integer between 20 and 6000;
- and
- each R1 is independently selected for each occurrence from hydrogen, acetyl,
- wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and at least 2% of R1 substituents are
- wherein the method improves (e.g., enhances, increases) mucociliary transport or clearance,
- thereby treating a mucosal disease or disorder.
A method for treating a subject suffering from a gastrointestinal disease or disorder, comprising administering an effective amount of a poly (acetyl, arginyl) glucosamine (PAAG) comprising the following formula (I):
- wherein:
- n is an integer between 20 and 6000;
- and
- each R1 is independently selected for each occurrence from hydrogen, acetyl,
- wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and at least 2% of R1 substituents are
- wherein the method improves (e.g., enhances, increases) mucociliary transport or clearance,
- thereby treating the gastrointestinal disease or disorder.
A method for treating a subject suffering from a pulmonary disease or disorder (e.g., improving lung function (e.g., improving the forced expiratory volume in 1 second (FEV1))), comprising administering an effective amount of a poly (acetyl, arginyl) glucosamine (PAAG) comprising the following formula (I):
- wherein:
- n is an integer between 20 and 6000;
- and
- each R1 is independently selected for each occurrence from hydrogen, acetyl,
- wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and at least 2% of R1 substituents an
- wherein the method improves (e.g., enhances, increases) mucociliary transport or clearance,
- thereby treating the pulmonary disease or disorder.
A dosage form configured for oral administration, comprising:
- a PAAG comprising the following formula (I):
- wherein:
- n is an integer between 20 and 6000;
- and
- each R1 is independently selected for each occurrence from hydrogen, acetyl,
- wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and at least 2% of R1 substituents are
- further comprising a neutral osmol agent (i.e., an agent for achieving neutral osmotic balance).
A nebulizer solution composition configured for inhaled administration, comprising:
- a PAAG comprising the following formula (I):
- wherein:
- n is an integer between 20 and 6000;
- and
- each R1 is independently selected for each occurrence from hydrogen, acetyl,
- wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and at least 2% of R1 substituents are
- further comprising a neutral osmol agent (i.e., an agent for achieving neutral osmotic balance).
Dependencies are inferred from the claim text.